Viridian Therapeutics, Inc.
VRDN
$12.38
-$0.43-3.36%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 4.86% | -3.82% | -12.97% | -80.41% | -82.59% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 4.86% | -3.82% | -12.97% | -80.41% | -82.59% |
| Cost of Revenue | 46.46% | 16.83% | 82.91% | 48.12% | 27.38% |
| Gross Profit | -46.54% | -16.86% | -83.27% | -49.76% | -28.76% |
| SG&A Expenses | -28.38% | -35.70% | 9.23% | 42.11% | 81.27% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 41.63% | 17.50% | 21.93% | 18.39% | 30.47% |
| Operating Income | -41.67% | -17.52% | -21.98% | -19.08% | -31.50% |
| Income Before Tax | -41.35% | -13.55% | -18.66% | -15.24% | -26.57% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -41.35% | -13.55% | -18.66% | -15.24% | -26.57% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -41.35% | -13.55% | -18.66% | -15.24% | -26.57% |
| EBIT | -41.67% | -17.52% | -21.98% | -19.08% | -31.50% |
| EBITDA | -41.79% | -17.55% | -21.98% | -19.03% | -31.43% |
| EPS Basic | -7.59% | 26.30% | 44.25% | 42.85% | 34.79% |
| Normalized Basic EPS | 5.96% | 25.57% | 15.49% | 12.78% | 3.36% |
| EPS Diluted | -7.59% | 26.30% | 44.25% | 42.85% | 34.79% |
| Normalized Diluted EPS | 5.96% | 25.57% | 15.49% | 12.78% | 3.36% |
| Average Basic Shares Outstanding | 47.54% | 51.78% | 42.05% | 36.62% | 37.01% |
| Average Diluted Shares Outstanding | 47.54% | 51.78% | 42.05% | 36.62% | 37.01% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |